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Abstract 
 
 Previous research has revealed circadian differences in locomotor ability corresponding to 
improved performance during active period. Nitric oxide (NO) production by the enzyme neuronal nitric 
oxide synthase (nNOS) exhibits circadian variation in the cerebellum. Considering the distribution and 
circadian variation of nNOS in the cerebellum, I hypothesized that NO could mediate daily rhythms in 
motor learning. The present study used the compound 7-nitroindazole (7-NI) to selectively inhibit nNOS 
during only times of investigative interest to circumvent the possibility for developmental compensatory 
mechanisms in nNOS knock-out (nNOS
-/-
) mice which lack nNOS throughout life. Mice were given 
intraperitoneal injections of either vehicle or 7-NI twice daily (1h prior to when lights were illuminated 
and before lights were extinguished) under a 12:12 (light:dark) photoperiod. Following lights on/off on 
the tenth day of injections groups were trained on an accelerating rotorod (4-40rpm) and tested 12 h later 
recording latency to fall. Four groups were formed based on treatment and time of behavioral analysis: A 
vehicle and a 7-NI group were trained in the morning and tested at night, and a vehicle and 7-NI group 
were trained at night and tested in the morning. I hypothesized 7-NI treatment would result in impaired 
locomotor ability and learning regardless of time of day and that vehicle treated groups would display the 
endogenous rhythm of locomotor ability. At the onset of the resting period vehicle treated mice exhibited 
impaired locomotor ability in accordance with the endogenous circadian rhythm, whereas 7-NI treated 
individuals lacked circadian variation of locomotor ability. NO expression was implicated in the circadian 
variation of locomotor ability. Immunocytochemical labeling of L-citrulline, a reliable marker of nNOS 
activity, will quantify the influence of nitric oxide expression in the cerebellum on circadian differences 
in locomotor ability and learning.  
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Introduction 
 The labile molecule nitric oxide (NO) was first characterized physiologically as an endothelium-
derived vasodilator by its effect in relaxing smooth muscle cells in blood vessels (Palmer, R., et. al., 
1987) and shortly after as a neurotransmitter in granule cells (Garthwaite et. al., 1988). NO is 
stoichiometrically produced as a free radical by the enzyme nitric oxide synthase (NOS) in the oxidation 
of L-arginine to L-citrulline. Three isoforms of NOS have been identified, neuronal (nNOS; (1)) in the 
brain, inducible (iNOS; (2)) in macrophages, and endothelial (eNOS;(3)) in blood vessels.  NO exhibits a 
slight increase in polarity when compared to O2, however retains the capacity to freely diffuse across cell 
membranes. Following production, NO diffuses from the point of origin, exhibiting a maximal 6 second 
half-life. Targets of NO include iron-containing heme groups, superoxide (O2
2-
) anions, and most notably 
in the brain, soluble guanylyl cyclase (sGC) (Schuman, E.M., & Madison, D.V., 1994). NO production by 
constitutively expressed nNOS exhibits dependence on calmodulin, hence cytosolic Ca
2+
, thus NO is 
produced upon calcium influx to nNOS containing cells(Zhou, L. and Zhu, D., 2009). nNOS is most 
highly expressed in the cerebellum, however is expressed throughout the brain (Ayers, N.A., et al., 1996).  
 Cerebellar function influences balance, posture, coordination, and eye tracking as well as 
sequential, repetitive, and rapidly alternating movements. Inputs from the cerebral cortex, brainstem, and 
spinal cord encode the actual and intended movement of the organism to the cerebellum via mossy fibers. 
Climbing fibers convey motor errors perceived consciously by the cerebral cortex or by visual and/or 
vestibular systems. Purkinje cells differentially receive these inputs and provide inhibitory output to three 
pairs of deep cerebellar nuclei which fire in task-specific rates and patterns on cortical premotor and 
spinal cord motor systems. The function of the cerebellum is to compare the intended and actual 
movements of the organism and correct for discrepancies. Cerebellar lesion or removal does not affect 
strength or sensation, however, result in uncoordinated, spastic movement, hence the cerebellum modifies 
and coordinates the range, force, and timing of movements (Kandel, 2000). 
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 The profoundly uniform organization of the cerebellar cortex was first documented by Ramón y 
Cajal in the early 1900s as having 5 types of neurons organized in 3 layers. Granule cells populate the 
innermost, granule cell layer of the cerebellar cortex interspersed with GABAergic Golgi interneurons. 
Granule cells axons project to the outermost molecular layer where they bifurcate to form parallel fibers. 
Parallel fibers form excitatory synapses on inhibitory basket, stellate, and Purkinje cells within the 
molecular layer. The cell bodies of Purkinje cells form the intermediate, Purkinje cell layer of the 
cerebellar cortex. Inhibitory Purkinje cells provide the sole, inhibitory output of the cerebellar cortex to 
deep cerebellar nuclei which is differentially influenced by mossy and climbing fiber input (Reviewed in 
Ito, 2001; Ito, 2006; Kandel, 2000). 
 The cerebellum contributes to the improvement seen in the range, force, and timing of repeated 
movements by modifying the relative efficacy with which excitatory mossy and climbing fibers stimulate 
Purkinje cell output on deep cerebellar nuclei. Long-term potentiation (LTP) at the parallel fiber-Purkinje 
cell synapse is the increase in synaptic efficacy seen following parallel fiber input to Purkinje cells in the 
absence of perceived error. If an error is perceived, climbing fiber input from the sensory field of the error 
induces long-term depression (LTD), a decrease in efficacy, at the parallel fiber-Purkinje cell synapse. 
LTD temporarily "relieves" the Purkinje cell of parallel fiber input, hence "relieves" deep cerebellar 
nuclei from its inhibition - altering their firing pattern on the respective motor system. It is through this 
"error-driven" modification of rate and pattern of deep cerebellar nuclei discharge on motor systems as 
mediated by Purkinje cell synaptic efficacy that the cerebellum contributes to the improvement in the 
range in force of motor tasks seen with repeated trials. The nitric oxide pathway is 1 of 7 routes of 
inducing cerebellar LTD (Ito, 2001) 
 In the cerebellum nNOS is found in granule, basket, and stellate cells. Following stimulation from 
mossy fiber inputs, which induces LTP at parallel fiber-Purkinje cell synapses, NO is produced in parallel 
fibers which simultaneously induces LTD at the parallel fiber-Purkinje cell synapse. During conjunctive 
mossy and climbing fiber input, glutamate spillover at climbing fiber-Purkinje cell synapses spurs NO 
production in parallel fibers, basket and stellate cells, shifting the biochemical cascade equilibria to LTD 
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in neighboring cells (reviewed in Ito, 2001). In this light NO in the cerebellum functions to coordinate the 
activity of neighboring cells. 
  Wild-type mice exhibit a circadian rhythm of locomotor activity corresponding to comparatively 
improved locomotor performance during the active period (Kriegsfeld, L.J. et al. 1999a). Circadian 
variation of NOS activity has been demonstrated throughout the brain, with peak NO production observed 
during the active period in all regions (Ayers, N.A., et al., 1996). Additional evidence has been provided 
which suggests that NOS exhibits peak activity in the molecular layer of the cerebellar cortex during the 
resting period (Demas, G. E., unpublished results). Because the Ayers study assessed NO production in 
homogenized tissue and the Demas study in cerebellar slices, these findings may not necessarily conflict. 
As opposed to non-specific NOS inhibitor-treated mice, the endogenous circadian locomotor activity 
rhythm and photoperiod entrainment capacity are not disrupted in nNOS genetic knock-out (nNOS
-/-
) 
mice (Kriegsfeld, L.J. et al. 1999a), but nNOS
-/-
 mice fail to exhibit the expected improvement in 
locomotor ability during the active period seen in WT mice as accessed by balance on a pole (Kriegsfeld, 
L.J. et al. 1999b). However, a number of considerations must be made when considering such data with 
regards to the absence of the gene throughout development, an example of which being the potential for 
compensatory mechanisms which may serve to spare function. 
 To circumvent confounding influences posed by compensatory mechanisms in the knock-out 
model and non-specific inhibition of NOS seen in traditional NOS inhibitors, the present study uses a 7-
nitroindazole (7-NI) to selectively inhibit nNOS. 7-NI is reported to reversibly bind with nNOS in an L-
arginine fashion with equal potency to non-selective NOS inhibitors, preventing binding and subsequent 
NO production (Babbedge, R.C., et al., 1993). The specificity of 7-NI for nNOS and not eNOS has been 
ascribed to its differential uptake by neurons and epithelial cells (Southan & Scabó, 1996). The present 
study aims to selectively inhibit NO production in neuronal populations during only times of investigative 
interest. 
 I examined the influence of NO on circadian variation previously observed in locomotor ability. I 
hypothesized that NO may mediate the circadian differences observed in motor ability such that when 
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nNOS production of NO is blocked, circadian variation  of locomotor ability is likewise impaired. 
Conversely, in animals where NO production is undisturbed circadian variation of locomotor ability will 
be observed corresponding to improved locomotor ability during the active period. In accordance with the 
role of NO in cerebellar LTD, selective inhibition of NO production in neuronal populations should elicit 
impaired motor task learning corresponding to reduced latencies to fall in testing trials. Quantification of 
L-citrulline production in cerebellar neurons will indicate a positive correlation between rotorod ability 
and learning and NO production in the cerebellum. Lack of NO production in the cerebellum will result in 
resting period-like rotorod ability with reduced learning. 
Methods 
 Three separate cohorts of mice were of mice were analyzed using the following protocol. 
Although procedural amendments were made and will be noted for each successive cohort, the majority 
of the procedure remained constant for all cohorts. 
Animals 
 A total of 116, six-week-old male C57bl/6 mice were obtained from Jackson Laboratory. Upon 
arrival mice were singly housed in polypropylene cages (dimensions: 27.8 x 17.5 x 13 cm) and provided 
food (Harlan Tech. Lab Rodent Diet 8640) and filtered tap water ad libitum. Mice were housed under a 
12:12 (light:dark) photoperiod for the duration of the experiment with the light phase beginning at 0600h 
Eastern Standard Time (EST) in the first cohort, and 0700h EST in the second and third cohorts. 
Treatment 
 Groups were randomly formed with regards to time of testing and treatment administered. 
Following a one-week photoperiod habituation period, mice were weighed to calculate treatment dosages 
which would be administered at 50 mg/kg. 7-NI solution was prepared twice daily in corn oil at 12.5 
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mg/mL. For the first and second cohorts, 7-NI solution was left on a shaker in the dark no fewer than 10h 
prior to use, whereas in the third cohort 7-NI was sonicated until in solution, then incubated at 37°C for 
no fewer than 10h in the dark prior to use.  Intraperitoneal (i.p.) injections were administered twice daily 
beginning at 0500h and 1700h in the first cohort, and 0600h and 1800h in the second and third cohorts for 
10 days prior to behavioral testing and were continued throughout testing. Mice were placed back in their 
cages following injections. 
Behavioral Testing 
 In all cohorts four training trials and three testing trials - a trial consisted of one run on the 
accelerating rotorod from 4-40 rpm - were recorded for each individual on the accelerating rotorod. In the 
first two cohorts behavioral testing was conducted within the vivarium, whereas in the third cohort mice 
were transported via a light-tight box to a behavioral suite following injections.  Trials began 1h after 
injections (0600h and 1800h for the first cohort and 0700h and 1900h for the second and third cohorts) to 
allow adequate time for 7-NI absorption. In the first cohort no maximum time limit was enforced, 
whereas in the second and third cohorts trials were terminated after 300 s. For the first and second 
cohorts, following each trial mice were placed back into their cages on the cage rack while other mice 
were tested. After all mice had completed the round of trials, the next round of trials would be conducted 
using the same order of mice. Sequential trials were used in the third cohort of mice. Following each trial, 
mice were placed back in the cage on the testing table for 10 s before the next trial would commence. 
Ethanolic solution (70%) was used to sterilize the rotorod between trials in the first and second cohorts, 
and after sequential trials for each individual in the third cohort.  
Perfusions    
 Following the final testing trial, mice were anesthetized with isoflurane vapors and given an 
overdose of sodium pentobarbital. Blood samples were collected from the retro-orbital sinus and placed 
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on ice. Perfusion of ice cold phosphate buffered saline (PBS) through the left ventricle of the heart was 
followed by a fixative solution (3% paraformaldehyde/1% gluteraldehyde in PBS). Brains were removed 
and postfixed for no longer than 8h and then transferred to 30% sucrose solution. Upon sinking in the 
sucrose solution, brains were flash frozen using dry ice and stored at -80°C until processing.  
Immunohistochemistry 
 One brain from randomly selected mice in each group in the first cohort were coronally sectioned 
(40 μm) on a cryostat at -23°C. Sections were collected in 30% sucrose antifreeze solution and stored at -
20°C until immunohistochemical processing. Free-floating sections were washed and permeabilized 3 x 5 
min with 0.5% Triton-X (TX) 0.1M phosphate buffered saline (PBS) solution then incubated for 1 h on a 
shaker in 0.5% sodium borohydride and 0.2% sodium metabisulfite PBS solution. Following incubation, 
sections were washed again using similar protocol, then incubated for an additional 1 h in 5% normal goat 
serum (NGS) and 0.5% TX in 0.1 M PBS solution on a shaker. The NGS solution was removed and 20 
μL (1:1000) rabbit anti-citrulline antibody in 5% NGS, 0.5% TX, 0.1M PBS solution was applied and left 
to incubate for 48 h on a shaker. The sections were washed again using the said protocol, then 20 μL 
(1:1000) biotinylated goat anti-rabbit antibody in 0.1M PBS with 0.5% TX and 5% NGS was applied and 
left to incubate for 90 min on a shaker.  During the incubation time, avidin-biotin complex (ABC) was 
prepared and left to sit for 30-60 min at -4°C. Sections were washed 3 x 5 min with 0.1 M PBS, then ABC 
was applied to amplify the secondary, biotinylated goat anti-rabbit, antibody and left to incubate for 1 h 
on a shaker. Following another wash, 3 x 5 min with 0.1 M PBS, L-citrulline staining was developed 
using diaminobenzidine (DAB) with hydrodrogen peroxide and nickel for 45 s. After a final wash, 2 x 5 
min in 0.1 M PBS, sections were mounted on slides with distilled water, dehydrated for 2 min each in 
95%, then 3 x 100% enthanolic solution, cleared with 3 x 2 min washes in xylene, then coverslipped 
using Permount.  
Behavioral Data Analysis 
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 Latency to fall and fecal boli data were analyzed using SPSS. Uni-, and multivariate ANOVA and 
Student's T-test comparisons of locomotor performance as assessed by latency to fall, time of day, and 
treatment were made between groups. Findings were considered significant if (p ≤ 0.05). 
Results 
 I examined the circadian locomotor influence of nNOS inhibition by 7-NI with the accelerating 
rotorod. Because the experimental protocol was modified between 3 cohorts of mice, the data from each 
cohort must be interpreted separately. In fact, a multivariate ANOVA indicates significant differences 
between cohorts (p < 0.05). 
 In the first cohort a multivariate ANOVA comparing time of testing and treatment revealed a 
trend of treatment on the latency to fall in training trials but not in testing trials. A Univariate ANOVA 
follow-up analysis confirmed this treatment effect in training trials (F(1,1) = 6.329, p < 0.05; Figure 1, left).  
 
 There was no effect of 7-NI treatment in the second cohort of mice in training or in testing, 
presumably due to 7-NI precipitating out of solution before injections (Figure 2, below).   
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 In the third cohort an effect of treatment was reestablished in training, indicated by a multivariate 
ANOVA (F(1,1) = 3.549, p = 0.047), however in the opposite direction. Univariate ANOVA follow-up 
analysis confirms this finding (F(1,1) = 7.371, p < 0.05; Figure 3, left). As in all cohorts there was no effect 
of treatment on testing trials. 
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 There were no differences observed between treatment, or time of day groups in motor learning 
as assessed by the difference in average testing and training latencies to fall. Fecal boli production, a 
measure of sympathetic activation (Taché, Y., & Bonaz, B., 2007), was significantly different with 
regards to time of day in all cohorts as shown by a Student's T-test in both training (F(1,1)= 21.913, p < 
0.001) and testing (F(1,1)= 4.583, p < 0.001). A significant effect of treatment on fecal boli production in 
training trials was identified by a Student's T-test in the first (F(1,1)= 0.026, p < 0.05) and third cohorts 
(F(1,1)=1.957, p < 0.001), but not in the second cohort. This effect was also seen in testing of the third 
cohort (F(1,1)=6.306, p < 0.01), but not in the first two cohorts. 
 Immunohistochemical staining for L-citrulline has identified nNOS activity during the active 
period (below). Sections shown were taken from the first cohort of mice to verify 7-NI treatment. As 
noted, there was a significant effect of treatment in the first and third cohorts. 
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Discussion 
 Although a significant effect of 7-NI on locomotor ability was observed, lack of significant 
circadian variation of locomotor ability in vehicle-treated groups limits the statistical power of these data. 
The present findings cannot be attributed to inhibition of nNOS exclusively in the cerebellum as 7-NI was 
administered intraperitoneally. Indeed, 60 minutes after i.p injections of 7-NI nNOS was shown to be 
significantly inhibited in the cerebellum, cerebral cortex, hippocampus, and adrenal gland (Babbedge, 
R.C. et al., 1993). With regards to the lack of circadian variation in vehicle treated animals, I suspect 
twice daily intraperitoneal injections may have interfered with the circadian rhythms of individuals in all 
cohorts, whether it be due to the injections, handling, sore abdomens , or large pockets of oil reported in 
the animals post mortem. It must also be noted that corticotropin-releasing hormone (CRH) release from 
climbing fibers is also implicated in LTD induction at Purkinje cell synapses (Miyata, M. et al., 1999) and 
that this system may also have been disrupted due to the treatment regimen. Immunohistochemical 
staining for L-citrulline, a reliable marker of nNOS activity (Martinelli, G.P.T., et al., 2002), has 
identified NO to be produced during the active period (night) in the cerebellum, however,  as circadian 
variations appear to have been disrupted, these data must be interpreted with caution. The present data 
show that NO expression in the cerebellum is without effect on the circadian variation of motor learning, 
however the methods employed did not permit a complete examination of the role of NO in this behavior. 
 In behavioral tests inhibition of nNOS by 7-NI has been shown to be antinociceptive (Moore, 
P.K., et al., 1993) and contribute to aggression (Demas, G.E., et al., 1997). Inhibition of nNOS has also 
been shown to promote the release of norepinephrine (Kiss, J.P. et al., 1996) and dopamine from 
hippocampal and striatal neurons (Silva, M.T. et al., 1995) as well as modulate serotonin turnover 
(Chiavegatto, S., et al., 2001). At low doses (1-5 nmol) 7-NI had anxiolytic effects in the elevated plus 
maze and antidepressant effects in the forced swim test, whereas at high doses (10 nmol) the opposite 
effects were observed (Spiacci, Jr., A., et. al., 2008). In the first two cohorts, 7-NI was noted to have 
begun precipitating out of solution before injections. In the third cohort of mice, sonication and 
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incubation of 7-NI (Chi, Z. et al., 2003) aided in keeping 7-NI in solution for injections. Indeed, the 
largest effect of treatment was observed in the third cohort. If the dose in the third cohort was above the 
threshold for anxiogenic and depressogenic effects of 7-NI, and the first two cohorts were below, it may 
help to explain the reversal of trends observed. This may also have implications regarding the CRH-
mediated LTD induction. 
 Stress-elicited responses have long been documented in rodents (Selye, H., 1937). In response to 
environmental stressors, CRH is released by the hypothalamus  signals the release of norepinephrine (NE) 
from the locus coeruleus (Valentino, R.J. et al., 1993) and  adrenocorticotrophic hormone (ACTH) from 
the pituitary, which further signals the release of glucocorticoids (GCs) and catecholamines (NE, and  
epinephrine (EPI)) from the adrenal glands. CRH immunoreactive cells are located throughout the central 
nervous system (Cummings, S. et al., 1983). Exogenous CRH administration has been shown to increased 
heart rate, blood pressure, activation in areas of the brain associated with arousal (Ehlers, C.L. et al., 
1983) and in behavioral tests be anxiogenic (Fisher, L.A., 1989), enhance learning at low doses, and 
stimulate locomotor and exploratory activity (Sutton, R.E. et al., 1982; Eaves, M. et al., 1985). In the 
cerebellum, immunohistochemistry localizes CRH to climbing fibers (Palkovits, M. et al. 1987) and in 
situ hybridization of the CRH receptor mRNA identifies type 1 CRH receptors in deep cerebellar nuclei 
as well as in Purkinje and granule cells (Potter, E. et al., 1994). Climbing fiber-released CRH has been 
implicated in LTD at Parallel fiber-Purkinje cell synapses in the cerebellum, indicated by the ability of 
CRH receptor antagonists to abolish LTD induction, but not maintenance, in cultured Purkinje cells. This 
study further showed that the CRH-mediated response is without effect on the NO-mediated response 
(Miyata, M. et al., 1999). Taken together, the anxiogenic/depressogenic effects of high doses of 7-NI 
coupled with increases in CRH due to treatment stress may help to explain the reversal of trends seen in 
the third cohort. 
 Locomotor ability and learning in third cohort mice were assessed using a different rotorod 
protocol than in the first two cohorts. In the third cohort, only 10 s was allotted between trials, whereas in 
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the first and second cohorts, an average of 96, and 26 min between training trials and 81, and 19 min 
between testing trials, respectively, were given. It has been experimentally demonstrated that LTD 
progressively develops over an hour following induction (Karachot, L. et al., 2001). Additionally, there 
were notable age differences between cohorts. In the first and second cohorts, mice were tested between 
8-12 weeks of age, when nNOS expression is high in the cerebellum. In the third cohort, mice were tested 
at 23 weeks of age. Age-dependent decrease in nNOS expression in the cerebellum has been 
experimentally documented in rats, indicating a significant decrease between 2 and 6 months of age (Yu, 
W.-J. et al., 2000). If circadian variation of NO expression in the cerebellum does mediate circadian 
variation of locomotor ability, speculated age-dependent decreases of nNOS in the third cohort of mice 
may aid in explaining the observed lack of circadian variation.  
 Procedural changes implemented after the first and second cohorts warrant caution when 
considering the overall data. As noted in the methods section, I attribute the lack of treatment effect seen 
in the second cohort to 7-NI precipitating out of solution. I propose the reverse of trends seen in the third 
cohort may be due to the lack of appropriate time for LTD induction between trials and/or side effects of 
7-NI associated with inhibition of nNOS coupled with treatment stress. In all cohorts, circadian variation 
of locomotor ability was not observed in vehicle or 7-NI treated animals. No conclusions can be made 
from the present data. Systemic inhibition of nNOS has shown to confound the ability to test any specific 
function of NO as evidenced by the array of effects seen in knock-out and pharmacological studies. 
Future studies may seek methods of administering nNOS inhibiting compounds to regions of interest in 
vivo while minimizing disturbance to the subjects. 
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